Johnson & Johnson and its subsidiaries have approximately 131,900 employees worldwide engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field. The executive committee of Johnson & Johnson is responsible for the strategic operations and allocation of the resources of the company, overseeing and coordinating the activities of the innovative medicine and medtech business segments. The company competes with other companies both locally and globally, with competition existing in all product lines, particularly in research involving the development and improvement of new and existing products and processes. Management's commitment to create life-enhancing innovations is reflected in the $15.1 billion invested in research and development in 2023, which is crucial for addressing the unmet needs of society and delivering value to patients, consumers, and healthcare professionals. The company leverages extensive resources across the enterprise to innovate and execute with excellence, ensuring operational flexibility and market responsiveness. The innovative medicine segment achieved sales of $54.8 billion in 2023, with significant contributions from new products introduced in the past five years, while the medtech segment reported sales of $30.4 billion, reflecting operational growth driven by technology penetration and the adoption of new products. The company maintains a policy of pricing products responsibly, which is essential in an environment increasingly concerned with healthcare costs. The company has also initiated restructuring programs to streamline operations and focus on the most promising medicines, which includes exiting certain markets and product lines. The company's strategic management practices emphasize leveraging IT capabilities to enhance business processes and support organizational goals. The integration of digital solutions and technology functionalities within the business processes is vital for maintaining competitive advantage and operational efficiency. The company's commitment to innovation is further demonstrated by the successful launch of new drugs and the advancement of its pipeline through regulatory submissions and approvals. The company’s approach to resource allocation and investment decisions reflects an understanding of market dynamics and the need for agility in responding to external influences. The ability to mobilize and deploy IT-based resources in combination with other capabilities is essential for transforming the firm into a competitive force, ultimately impacting firm performance and delivering business value. The company’s focus on information management capability ensures the provision of data and information to users with appropriate levels of accuracy, timeliness, reliability, and security, which is critical for effective decision-making and operational success.